Core Insights - Virios Therapeutics is advancing a combination therapy of valacyclovir and celecoxib (IMC-2) for treating Long-COVID (LC) symptoms, following a positive proof of concept study that showed improvements in fatigue, pain, and overall health compared to untreated controls [2][4][9] - The company has completed enrollment for its investigator-initiated LC study, with top line results expected in October 2024 [4] - The National Center for Health Statistics estimates that 17.6% of the U.S. population, or nearly 45 million adults, have experienced Long-COVID since the pandemic began, highlighting a significant unmet medical need [5] Company Overview - Virios Therapeutics focuses on developing novel antiviral therapies for chronic diseases linked to viral infections, including fibromyalgia and Long-COVID [10] - The company’s lead candidates are fixed-dose combinations of antiviral compounds and celecoxib aimed at reducing symptoms associated with herpesvirus activation [10] - IMC-1, a combination of famciclovir and celecoxib, has received fast track designation from the FDA, indicating its potential significance in treating these conditions [10]
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center